Treatment of the hemophilias.
The treatment of hemophilia and conditions that frequently afflict hemophilic patients, such as arthropathy, HIV infection, and viral hepatitis, are discussed. Long-term prophylaxis with Factor VIII or IX is very successful at preventing disabling arthropathy. Much research is being done on gene therapy and prolonged periods of Factor VIII and IX expression have already been achieved in animals. In HIV-seropositive hemophilic patients the CD4 count appears to decline more slowly in patients treated with higher purity than with lower-purity products. Thermoresistant non-lipid-enveloped viruses, such as parvovirus, do not become inactivated by the currently used virucidal methods.
Moll
S
S
University of North Carolina, Chapel Hill, USA.
White
G C
GC
D001779:Blood Coagulation Factors / Q000627:therapeutic use; D007562:Creutzfeldt-Jakob Syndrome / Q000635:transmission; D015316:Genetic Therapy; D006467:Hemophilia A / Q000628:therapy*; D006470:Hemorrhage / Q000517:prevention & control; D006525:Hepatitis, Viral, Human / Q000635:transmission; D006801:Humans; D065227:Transfusion Reaction; D014777:Virus Diseases / Q000635:transmission
D001779:Blood Coagulation Factors